CN102858753A - 用作二酰基甘油脂酶抑制剂的甘氨酸色满-6-磺酰胺 - Google Patents

用作二酰基甘油脂酶抑制剂的甘氨酸色满-6-磺酰胺 Download PDF

Info

Publication number
CN102858753A
CN102858753A CN2011800198869A CN201180019886A CN102858753A CN 102858753 A CN102858753 A CN 102858753A CN 2011800198869 A CN2011800198869 A CN 2011800198869A CN 201180019886 A CN201180019886 A CN 201180019886A CN 102858753 A CN102858753 A CN 102858753A
Authority
CN
China
Prior art keywords
acetic acid
cyclobutyl
methoxy
difluoro
phenyl sulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800198869A
Other languages
English (en)
Chinese (zh)
Inventor
L.S.查帕克
郑晓帆
丁敏
胡双华
黄雅忠
R.G.金特尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN102858753A publication Critical patent/CN102858753A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN2011800198869A 2010-02-19 2011-02-14 用作二酰基甘油脂酶抑制剂的甘氨酸色满-6-磺酰胺 Pending CN102858753A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30599610P 2010-02-19 2010-02-19
US61/305,996 2010-02-19
PCT/US2011/024726 WO2011103055A1 (en) 2010-02-19 2011-02-14 Glycine sulfonamides for use as inhibitors of diacylglycerol lipase

Publications (1)

Publication Number Publication Date
CN102858753A true CN102858753A (zh) 2013-01-02

Family

ID=43755254

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800198869A Pending CN102858753A (zh) 2010-02-19 2011-02-14 用作二酰基甘油脂酶抑制剂的甘氨酸色满-6-磺酰胺

Country Status (5)

Country Link
US (1) US8404741B2 (enExample)
EP (1) EP2536694B1 (enExample)
JP (1) JP2013520423A (enExample)
CN (1) CN102858753A (enExample)
WO (1) WO2011103055A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018005801A2 (en) * 2016-07-01 2018-01-04 Venenum Biodesign Llc Novel non-systemic tgr5 agonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1160248A1 (en) * 2000-05-31 2001-12-05 Pfizer Inc. N-(Isoxazol-5-yl)-sulfonamide derivatives and their use as endothelin antagonists
US20090264400A1 (en) * 2008-04-08 2009-10-22 Gruenenthal Gmbh Substituted Sulfonamide Compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1160248A1 (en) * 2000-05-31 2001-12-05 Pfizer Inc. N-(Isoxazol-5-yl)-sulfonamide derivatives and their use as endothelin antagonists
US20090264400A1 (en) * 2008-04-08 2009-10-22 Gruenenthal Gmbh Substituted Sulfonamide Compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BARTHELEMY NYASSE ER.AL.: "Synthesis and cathodic cleavage of a set of substituted benzenesulfonamides including the corresponding tevt-butyl sulfonylcarbamates:pK, of sulfonamides", 《J. CHEM. SOC. PERKIN TRANS.》 *
HEATHER S. HOOVER ET.AL.: "Selectivity of inhibitors of endocannabinoid biosynthesis evaluated by activity-based protein profiling", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *

Also Published As

Publication number Publication date
WO2011103055A1 (en) 2011-08-25
JP2013520423A (ja) 2013-06-06
EP2536694A1 (en) 2012-12-26
US8404741B2 (en) 2013-03-26
US20110207749A1 (en) 2011-08-25
EP2536694B1 (en) 2014-01-22

Similar Documents

Publication Publication Date Title
CA2691987C (en) Antibacterial agents
JP4054368B2 (ja) 置換メチルアリール又はヘテロアリールアミド化合物
KR100917068B1 (ko) 아세틸렌 유도체
MXPA06012830A (es) Compuestos de aril- o heteroaril-amida ortosustituidos.
JP2009535357A (ja) １１−β−ヒドロキシステロイドデヒドロゲナーゼ１の阻害剤
RS65642B1 (sr) Supstituisani pirazolo(1,5-a)pirimidini i njihova upotreba u lečenju medicinskih poremećaja
EP1893609A1 (en) N-(pyridin-2-yl)-sulfonamide derivatives
CA3129438A1 (en) Tyk2 pseudokinase ligands
US10370324B2 (en) Phenyl and pyridinyl hydroxamic acids
JP2013507369A (ja) Ｇタンパク質共役受容体８８の調節因子
CA2965467A1 (en) Kcnq2-5 channel activator
JP4644714B2 (ja) 新規なシクロヘキサン誘導体
CN102858753A (zh) 用作二酰基甘油脂酶抑制剂的甘氨酸色满-6-磺酰胺
WO2018211323A1 (en) Hetercyclic compounds for the treatment of disease
JP2022549435A (ja) Ｊａｋ阻害剤
EP3402780A1 (en) Mast-cell modulators and uses thereof
WO2020098710A1 (zh) 一种取代的双芳香基酰胺化合物及其制备方法和应用
CN101272774B (zh) 取代的丙烯酰胺衍生物和包含其的药物组合物
US6610714B2 (en) Non-nucleoside reverse transcriptase inhibitors
US8354548B2 (en) Glycine chroman-6-sulfonamides for use as inhibitors of diacylglycerol lipase
CN102512421B (zh) 哌嗪酰胺类化合物在制药中的应用
CN107663202B (zh) 3-(脲基-甲基)-4-芳基-吡啶衍生物及其制备方法和作为抗肝癌药物的应用
WO2017215586A1 (zh) 酰胺类衍生物、其制备方法及其在医药上的用途
MXPA06010629A (en) Phenylaminoethanol derivates as beta2 receptor agonists
JPWO2001016091A1 (ja) ビスシクロプロパンカルボン酸アミド化合物およびその医薬用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130102